ABSTRACT
ABSTRACT Objective The aim of the study was to assess the evidence on miRNAs as biomarkers for the diagnosis of endometriosis, as well as to provide insights into the challenges and strategies associated with the use of these molecules as accessible tools in clinical practice. Methods Systematic review conducted on PubMed®, Latin American and Caribbean Health Sciences Literature (LILACS), MEDLINE® and Web of Science databases using the search terms endometriosis (all fields) AND miRNA (all fields), evaluating all publication up to May 2019. Results Most miRNAs found to be dysregulated in this study were harvested from tissue samples, which precludes their use as a non-invasive diagnostic test. However, differential expression of 62 miRNAs was reported in samples that may be used for non-invasive diagnosis of endometriosis, such as blood, serum and plasma. Conclusion Despite the identification of several candidates, studies are investigatory in nature and have been conducted with small number of samples. Also, no particular miRNA has been validated for diagnostic purposes so far. Studies based primarily on biological samples and applicable to translational research are warranted. Large databases comprising information on sample type and the use of saliva and vaginal fluid for miRNAs identification may prove essential to overcome current barriers to diagnosis of endometriosis.
RESUMO Objetivo O objetivo do estudo foi analisar as evidências sobre miRNAs como biomarcadores para o diagnóstico de endometriose, bem como levantar informações sobre os desafios e as estratégias necessárias para tornar essas moléculas ferramentas acessíveis para uso na prática clínica. Métodos Revisão sistemática conduzida nos bancos de dados PubMed®, Literatura Latino-Americana e do Caribe em Ciências da Saúde (LILACS), MEDLINE® e Web of Science utilizando os termos de pesquisa "endometriosis" (todos os campos) AND "miRNA" (todos os campos), avaliando todas as publicações até maio de 2019. Resultados A maioria dos miRNAs desregulados foram analisados a partir de amostras de tecido, o que inviabiliza seu uso como teste diagnóstico não invasivo. Todavia, 62 miRNAs foram identificados como diferencialmente expressos em amostras que poderiam ser usadas para o diagnóstico pouco invasivo de endometriose, como sangue, soro e plasma. Conclusão Apesar de todos esses candidatos, os trabalhos são exploratórios, realizados com números pequenos de amostras, sem miRNAs específicos validados para fins diagnósticos. Estudos envolvendo principalmente amostras biológicas, visando à pesquisa translacional, deveriam ser mais explorados. O desenvolvimento de grandes bancos de dados sobre amostras, bem como o uso de saliva e fluido vaginal para identificação de miRNAs, poderia servir como recursos essenciais para as barreiras atuais no diagnóstico da endometriose.
Subject(s)
Humans , Female , MicroRNAs/genetics , Endometriosis/diagnosis , Endometriosis/genetics , Biomarkers , Caribbean RegionABSTRACT
Objective To investigate the expression of high mobility group protein box1 (HMGB1)in ovarian endometriosis tissue and to provide new idea for early diagnosis,treatment and prognosis of endometriosis.Methods The levels of HMGB1 in ectopic endometrium and eutopic endometrium of 69 patients with ovarian endometriosis and endometrium of 69 cases with non-endometrioses were detected by reverse transcription-polymerase chain reaction (RT-PCR) and Western-blotting.Results HMGB1 was expressed in all the three groups (ectopic endometrium eutopic endometrium endometrium with non-endometrioses).The relative expression level of HMGB1 mRNA was 0.54383 ± 0.0565,0.3016 ± 0.0614,and 0.1536 ±0.0444,respectively (F =377.923,P ＜ 0.0001).The relative of HMGB1 protein was 0.83990 ±0.12869,0.40100 ±0.16425,and 0.19986 ± 0.08162,respectively (F =185.625,P =0.0000).The expression level of HMGB1 was related to clinical stages (t =10.28,P ＜0.01) ; however,it was not obviously related to age,the diameter of lump,and course of disease (P ＞ 0.05).Conclusions Over expression of HMGB1 in ovary endometriosis indicates that HMGB1 plays a significant role in occurrence and development of ovary endometriosis.The expression of HMGB1 in endometriosis eutopic endometrium was much higher than that of non-endometrioses endometrium,which supports the eutopic endometrium determinism.The overexpression of HMGB1 was consistent with clinical stage,which proves that HMGB1 maybe be tightly associated with the severity of the disease and to likely become biomarker.
ABSTRACT
@# ObjectiveTo discuss the clinical value of serum CA125 and endometrial antibody (EMAb) for the diagnosis of endometriosis.Methods216 patients were determined by the presences of CA125 and EMAb before operation.ResultsAll cases were diagnosed by pathology after operation. CA125 positive rate in the endometriosis group was 58.3% and that in the control group was 12.5%. The difference between two groups was significant (P<0.01).EMAb positive rate in the endometriosis group was 31.3% and that in the control group was 14.3%. The difference between two groups was also significant (P<0.01). When determining CA125 alone to diagnose endometriosis, the sensitivity rate was 58.3% and specificity rate was 87.5%. If determining EMAb alone to diagnose endometriosis, the sensitivity rate was 31.3% and specificity rate was 85.7%. When one of them was used as diagnostic criterion, the sensitivity and specificity were 64.6% and 73.2% respectively. If combining use of both CA125 and EMAb as diagnostic criterion, the sensitivity and specificity were 25.0% and 100% respectively.Conclusions The determination of serum CA125 or EMAb levels is helpful for the qualitative diagnosis of endometriosis, especially using them combined, the diagnostic accuracy may be enhanced.